Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi5-vi7; doi:10.1093/annonc/mdm215
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gebbia, V
Right arrow Articles by Maiello, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gebbia, V
Right arrow Articles by Maiello, E
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

monoclonal antibodies anti-EGFR and anti-VEGF

Cetuximab in squamous cell head and neck carcinomas

V Gebbia1,2,*, F Giuliani3, VM Valori4, R Agueli1, G Colucci3 and E Maiello4

1 Medical Oncology Unit, La Maddalena Hospital, Palermo
2 Department of Experimental Oncology and Clinical Applications, University of Palermo, Palermo
3 Medical Oncology Unit, National Cancer Institute, Bari
4 Medical Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy

* Correspondence to: Dr V. Gebbia, Dipartimento Oncologico, La Maddalena, via san Lorenzo Colli n. 312d, Palermo, Italy. Tel: +39-09-16806710; Fax: +39-09-16806906; E-mail: vittorio.gebbia{at}tin.it

The epidermal growth factor receptor (EGFR) antagonist, cetuximab, has recently been shown to enhance the effects of radiotherapy, and reports to date indicate that this effect occurs without any change in the pattern and severity of toxicity usually associated with head and neck radiation and/or chemotherapy (CT) administration. Moreover, several studies have reported that the expression of EGFR is strongly linked to poor outcome in patients undergoing therapy. Therefore, the presence of the EGFR in almost all cases of head and neck carcinoma offers a new therapeutic opportunity to most patients. In this paper, we report a review of the major studies dealing with the use of cetuximab in advanced head and neck cancer.

Key words: cetuximab, head and neck cancer, EGFR, patient outcome, chemotherapy, toxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.